Abstract
Human adult skeletal stem cells, a.k.a. mesenchymal stem cells or marrow stromal cells (MSCs), have been identified as precursors of several different mesenchymal cellular lineages, including osteoblasts, chondrocytes, myoblasts, adipocytes, and fibroblasts, as well as non-mesenchymal lineages including neurons and glial cells. Adult stem cell transplantation is a promising strategy for the treatment of stroke. MSCs are also used as a platform for gene therapies and therapeutic agents. In this review, we discuss recent progress of human skeletal stem cell biology, in vitro differentiation of MSCs into neural stem cells and neurons, MSC therapy for stroke, MSC aging and the challenge of autologous cell therapy for stroke in elderly patients.
Keywords: Cell therapy, elderly patients, human skeletal stem cells, MSCs, aging, stroke, mesenchymal stem cells, marrow stromal cells, gene-modified MSCs, neurons, neural stem cells, Adult stem cell transplantation, gene therapy, stem cell aging, stem cell biology, autologous cell therapy, neurogenesis, A brief history of MSCs, the origin of mesenchymal stem cells, differentiation, ICH, Ischemic stroke, CNS, trophic factor, Clinical trials
Central Nervous System Agents in Medicinal Chemistry
Title: From Bone to Brain: Human Skeletal Stem Cell Therapy for Stroke
Volume: 11 Issue: 2
Author(s): Shuanhu Zhou
Affiliation:
Keywords: Cell therapy, elderly patients, human skeletal stem cells, MSCs, aging, stroke, mesenchymal stem cells, marrow stromal cells, gene-modified MSCs, neurons, neural stem cells, Adult stem cell transplantation, gene therapy, stem cell aging, stem cell biology, autologous cell therapy, neurogenesis, A brief history of MSCs, the origin of mesenchymal stem cells, differentiation, ICH, Ischemic stroke, CNS, trophic factor, Clinical trials
Abstract: Human adult skeletal stem cells, a.k.a. mesenchymal stem cells or marrow stromal cells (MSCs), have been identified as precursors of several different mesenchymal cellular lineages, including osteoblasts, chondrocytes, myoblasts, adipocytes, and fibroblasts, as well as non-mesenchymal lineages including neurons and glial cells. Adult stem cell transplantation is a promising strategy for the treatment of stroke. MSCs are also used as a platform for gene therapies and therapeutic agents. In this review, we discuss recent progress of human skeletal stem cell biology, in vitro differentiation of MSCs into neural stem cells and neurons, MSC therapy for stroke, MSC aging and the challenge of autologous cell therapy for stroke in elderly patients.
Export Options
About this article
Cite this article as:
Zhou Shuanhu, From Bone to Brain: Human Skeletal Stem Cell Therapy for Stroke, Central Nervous System Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152411796011376
DOI https://dx.doi.org/10.2174/187152411796011376 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Molecular Modeling, Molecular Dynamics and Bioinformatics in Pharmaceutical Design)
Current Pharmaceutical Design Inhibitors of Cyclin-Dependent Kinases: Potential Drugs for the Treatment of Neurodegenerative Disorders?
Current Medicinal Chemistry - Central Nervous System Agents Anti-oxidant and Antiproliferative Activities of Mongolian Medicinal Plant Extracts and Structure Isolation of Gnetin-H Compound
Medicinal Chemistry An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Potential Targets for the Development of Novel Antidepressants: Future Perspectives
CNS & Neurological Disorders - Drug Targets REM sleep and its Loss-Associated Epigenetic Regulation with Reference to Noradrenaline in Particular
Current Neuropharmacology Metabolic Alterations in the Outer Membrane Vesicles of Patients with Alzheimer’s Disease: An LC-MS/MS-based Metabolomics Analysis
Current Alzheimer Research The Delivery of Biologically Active (Therapeutic) Peptides and Proteins into Cells
Current Medicinal Chemistry Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Novel Targets in Multiple Sclerosis: To Oxidative Stress and Beyond
Current Topics in Medicinal Chemistry Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Current Neurovascular Research The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry Pituitary Adenylate Cyclase Activating Polypeptide in Animal Models of Neurodegenerative Disorders - Implications for Huntington and Parkinsons Diseases
Letters in Drug Design & Discovery The p35 Family of Apoptosis Inhibitors
Current Genomics Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
Current Alzheimer Research Editorial [Hot topic:Pigment Epithelium-Derived Factor (PEDF) in Health and Disease (Guest Editor: Sho-Ichi Yamagishi)]
Current Molecular Medicine Microglia in Alzheimer’s Disease
Current Alzheimer Research Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology